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Abstract 
Purpose: To determine the in vitro genotoxicity and mutagenicity of sitagliptin alone and in combination 
with three commonly used artificial sweeteners (saccharin, aspartame and acesulfame-k). 
Methods: The in vitro genotoxicity and mutagenicity of Sitagliptin alone and in combination with three 
popular artificial sweeteners (saccharin, aspartame and acesulfame-k) were evaluated by Comet and 
Ames assays, respectively. 
Results: Sitagliptin demonstrated mutagenic potential only to TA 98 with S9 mix at a concentration of 
3040 µg/plate. The mutagenicity of sitagliptin was enhanced when tested in combination with the 
artificial sweeteners. Furthermore, sitagliptin also caused pronounced DNA fragmentation at higher 
doses compared with negative control.   
Conclusion:  At higher doses, sitagliptin showed both mutagenicity and genotoxicity. Thus, long-term 
use of artificial sweeteners with sitagliptin may lead to increase in both mutagenicity and genotoxicity. 
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Oral anti-diabetic drugs are the first line therapy 
for type 2 diabetes, sitagliptin recently is being 
used as oral anti-diabetic drug for type-2 
diabetes management.  Sitagliptin effectively 
helps to maintain blood glucose level in diabetic 
patients and also enhances the activity of beta 
cells when used in combination with metformin 
[1]. However, sitagliptin treatment is linked to 
increased pancreatic ductal turnover, ductal 
metaplasia, and pancreatitis [2]. Significant 
association is seen between diabetes, diabetes 
therapies, and cancer [3]. In fact metabolic 
dysfunction influences tumorigenesis because of 
which obese and diabetic patients are at greater 
risk of cancer [4]. 
 
Artificial sweeteners are more often used by 
obese individuals in effort to lose weight. 
However, psychological problems, mental 
dysfunction, bladder cancer, heart failure and 
brain tumors are some alarming side effects of 
the artificial sweeteners [5]. Saccharin was the 
principal artificial sweetener but its potential 
tumergencity declined its fame [6].  Saccharin is 
also considered to be responsible for weakness, 
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low serum iron, vitamin A and folate level as well 
as high serum vitamin E and cholesterol level [7]. 
Aspartame is an artificial, non-saccharide 
sweetener and is considered to be closely linked 
with increased incidence of malignancy of brain 
tumors. It is suggested that long term use of 
aspartame might lead to improper antioxidant 
status of brain mainly through glutathione-
dependent system involvement [8]. 
 
Acesulfame K is a calorie-free sugar substitute, 
which is not metabolized by the body and is 
discharged unaltered.  Although it is largely 
excreted from the urine, studies suggest that it 
can be excreted to the amniotic liquid and milk 
[9]. The main objective of the present project was 
to evaluate the mutagenic and genotoxic 
potential of saccharin, aspartame, acesulfame-k 
and sitagliptin alone and in combination. 
Moreover, these chemical were not only tested in 
their original chemistry but their metabolites were 
also tested in vitro by using mouse liver rate 





Materials and chemicals  
 
Artificial sweeteners like saccharin, aspartame 
and acesulfame-k were obtained from Harmann 
Pharmaceuticals Pvt Ltd, India, while sitagliptin 
was provided by the Highnoon laboratories Ltd to 
carry out this project. Metabolic activation 
enzyme system (S9) was obtained from 
Environmental Bio-detection Products Inc. (EBPI, 





All procedures that involved animals were 
conducted in accordance with the National 
Institute of Health guide for the care and use of 
laboratory animals [10]. All experiment animals 
were approved by institutional review board (IRB) 
committee of Department of pharmacology and 
toxicology, University of Veterinary and Animal 
Sciences Lahore, Pakistan (ref no. 2011-VA-
537). Blood lymphocytes were used to evaluate 
the genotoxicity by comet assay. For this, blood 
lymphocytes of healthy sheep were obtained and 
separated by using lymphocytes separation 
media. Then the lymphocytes were exposed to 
various concentrations of the chemicals [11]. The 
exposed lymphocytes were mixed with 1 % low 
melting point agarose and layered onto the base 
slides. After solidification, third layer of agarose 1 
% was layered onto the same slide and allowed 
to solidify. Subsequently the slides were dipped 
in the lysing solution containing 2.5 M sodium 
chloride, 0.1 M ethylenediaminetetraacetic acid 
(EDTA), 10 mM Tris, 1 % Triton X-100 (pH 10) 
for 2 h. The slides were then exposed to alkaline 
buffer consisting 1mM EDTA and 300mM sodium 
hydroxide (pH > 13) for 20 min. The cells were 
subjected to electrophoresis for 20 min at 25 
volts and 300 mA. Slides were visualized by 
using fluorescent microscope. Phosphate buffer 
saline was used as negative control and 20 % 
DMSO was taken as positive control. DNA 
damage was evaluated by measuring the size of 
the comet of fragmented DNA. The results were 
recorded as described by the method designed 




Ames Salmonella/Microsome mutagenicity assay 
was performed with and without S9 metabolic 
system (+S9 and –S9 respectively) as illustrated 
by Mortelmans and Zeiger [13]. Two mutant 
strains of Salmonella typhimurium TA 100 and 
TA 98 obtained from environmental bio-detection 
products incorporation (EBPI) Canada for 
mutagenic testing of the drugs. 
 
Briefly, 0.05 mL of overnight grown culture of 
strain of Salmonella, 0.1 mL of the agents to be 
tested (diluted with PBS), 0.5 mL of S9 (+S9) 
were mixed and incubated for 30 min at 37 °C.  
After incubation, the mixture was homogenized 
with 2 mL of top agar was poured onto a minimal 
glucose media in petri plate. The test was run in 
in. Plates were incubated at 37 °C for 48 h and 
then revertant His+ bacteria colonies were 
scored.  In each assays, a positive (sodium 
azide) and a negative (PBS) control were also 
run. The mutagenic index (MI) was calculated as 
the ratio between number of histidine revertant 
induced per plate of the test chemical and 
spontaneous revertant of the negative control. 
Mutagenic response was considered positive 
when numbers of colonies in test chemical plate 





Statistical analysis was performed using SPSS 
software version 17, one-way ANOVA and Tukey 
statistical tests were used to compare the data. P 




The results show that increase in sitagliptin 
concentration resulted in a rise in its genotoxic 
potential. Maximum DNA damage was seen at 
the concentrations of 1520 µg/mL and 3040 
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µg/mL with damage index of 9 and 20 
respectively (Figure 1). 
 
Ames salmonella test when performed to 
evaluate the mutagenic capability of the 
sitagliptin (Table 1), it didn't demonstrate any 
significant mutagenic impact against TA100 and 
TA98 strains without the metabolic activation 
system. However significant mutation was seen 
in the presence of metabolic activation system 
against TA98 at the highest concentration of 
3040 µg/plate. 
 
Saccharin (Figure 1) demonstrated genotoxicity 
in dose dependent manner. The tail length 
increased significantly with respect to the 
negative control. Saccharin at the doses of 
20,000 µg/mL and 40,000 µg/mL exhibited the 
maximum damage index of 13 and 24 
respectively. The results of Ames assay (Table 
2) revealed that saccharin at concentration of 
2500 and 5000 µg/plate without S9 mix and at 
2500 µg/plate with S9 exhibited significant 
mutagenic effects against TA 98 strain. 
Saccharin however at all concentrations between 
2500 to 40,000 µg/plate did not revealed 
significant mutagenic potential against TA100 
with and without metabolic activation system. 
 
Aspartame results illustrated dose dependent 
increase in the length of the comet tail indicating 
increase in the DNA damage with increase in the 
concentration relative to the negative control 
(Figure 2).  
 
 
            Figure 1: Damage index of sitagliptin, saccharin and sitagliptin + saccharin 
 
Table 1: Mutagenic potential of sitagliptin 
 
No. Conc. Revertant colonies/plate 
(µg/plate) TA 100 TA 98 
  +S9 M.I. -S9 M.I. +S9 M.I. -S9 M.I. 
1 190 56 0.3 39 0.37 34 0.38 19 0.26 
2 380 68 0.36 40 0.38 42 0.47 22 0.3 
3 760 72 0.39 85 0.8 64 0.71 37 0.37 
4 1520 101 0.54 96 0.91 150 1.68 101 1.401 
5 3040 120 0.65 120 1.14 230 2.58 129 1.79 
Negative 
control 
0 184  105   89   72   
Positive 
control 
5 2096 11.39 758 7.21 563 6.325 360 5 
 





Conc. Revertant colonies/plate 
(µg/plate) TA 100 TA 98 
  +S9 M.I. -S9 M.I. +S9 M.I. -S9 M.I. 
1 2500 126 0.68 70 0.66 183 2.05 260 3.63 
2 5000 115 0.62 63 0.6 162 1.82 154 2.13 
3 10000 96 0.52 54 0.51 75 0.84 60 0.83 
4 20000 89 0.48 36 0.34 60 0.67 50 0.69 
5 40000 83 0.45 25 0.23 40 0.45 32 0.44 
Negative control 0 184  105   89   72   
Positive control 5 2096 11.39 758 7.21 563 6.33 360 5 
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          Figure 2: Damage index of sitagliptin, aspartame and sitagliptin + aspartame 
 
Mutagenic evaluation of aspartame (Table 3) 
demonstrated significant mutagenic effects 
against TA100 at the concentration of 150 
µg/plate and 300 µg/plate in the presence of 
metabolic system. 
 
Acesulfame-k exhibited significant dose 
dependent DNA damage to the lymphocytes as 
compared to the negative (Figure 3). 
 
Acesulfame-K exhibited mutagenic effects at 
concentration of 800 µg/plate and 1600 µg/plate 
against TA98 strain in the absence of metabolic 
activation system (Table 4). No significant 
numbers of colonies were seen on GM agar 









Revertant colonies/ plate 
TA 100 TA 98 
  +S9 M.I. -S9 M.I. +S9 M.I. -S9 M.I. 
1 150 369 2 86 0.81 54 0.6 42 0.58 
2 300 492 2.67 119 1.13 93 1.04 49 0.68 
3 600 210 1.14 80 0.76 83 0.93 57 0.79 
4 1200 192 1.04 62 0.59 79 0.88 34 0.47 
5 2400 176 0.95 60 0.57 75 0.84 21 0.29 
Negative control 0  184   105   89   72   
Positive control 5 2096 11.4 758 7.21 563 6.325 360 5 
 
 
 Figure 3: Damage index of sitagliptin, acesulfame-K and sitagliptin + acesulfame-K 
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Table 4: Mutagenic potential of acesulfame-K 
 
Acesulfame-K 
No. Conc. Revertant Colonies/plate 
(µg/plate) 
  
TA 100 TA 98 
+S9 M.I. -S9 M.I. +S9 M.I. -S9 M.I. 
         1 100 96 0.52 47 0.44 63 0.7 72 1 
2 200 123 0.66 52 0.49 79 0.88 102 1.41 
3 400 148 0.8 66 0.62 83 0.93 138 1.91 
4 800 154 0.83 87 0.82 129 1.44 220 3.05 
5 1600 169 0.91 95 0.9 133 1.49 231 3.2 
Negative Control 0 184  105   89   72   
Positive Control 5 2096 11.39 758 7.21 563 6.325 360 5 
 
In this project when the genotoxicity of sitagliptin 
was evaluated in combination with saccharin, the 
tail length increased in dose dependent fashion. 
Highest damage index of 31 was at the 
combination dose of 3040+40000 µg/mL (Figure 
1). When different combinations of sitagliptin and 
saccharin was tested outcomes turned out to be 
mutagenic at three measurements of 380+5000 
µg/plate, 760+10000 µg/plate and 1520+20000 
µg/plate to TA 98 both with and without S9 
mixture (Table 5). The outcomes were 
noteworthy when sitagliptin and saccharin 
consolidated measurements were compared with 
sitagliptin dosages alone. 
 
Similarly sitagliptin and aspartame when 
evaluated for genotoxicity (Fig 2), damage 
indices of 3, 5, 8, 13 and 22 represented dose 
dependent relationship with the concentrations. 
Results revealed no significant enhance in the 
genotoxicity of sitagliptin + aspartame as 
compared the genotoxic effects of sitagliptin 
alone. In case of sitagliptin + aspartame 
mutagenicity test (Table 6) results revealed that 
among all the combined doses of Sitagliptin and 
Aspartame, 760+600 µg/plate and 1520+1200 
µg/plate were mutagenic only to TA98 with S9 
mix. All of other combined doses were non-
mutagenic against both TA100 and TA98 with 
and without metabolic system. 
 
Table 5: Mutagenic potential of sitagliptin and saccharin in combination 
 
Sitagliptin + saccharin 
No. Conc. Revertant colonies/plate 
 (µg/plate) TA 100 TA 98 
  +S9 M.I. -S9 M.I. +S9 M.I. -S9 M.I. 
          1 190 + 2500 152 0.82 156 1.48 144 1.61 90 1.25 
2 380 + 5000 176 0.95 175 1.66 208 2.33 215 2.98 
3 760 + 10000 195 1.05 195 1.85 212 2.38 252 3.5 
4 1520 + 20000 152 0.82 199 1.89 360 4.04 266 3.69 
5 3040 + 40000 145 0.78 146 1.39 153 1.71 139 1.93 
Negative 
control 
0 184   105   89   72   
Positive 
Control 
5 2096 11.39 758 7.21 563 6.325 360 5 
 
Table 6: Mutagenic potential of sitagliptin and aspartame in combination 
 
Sitagliptin + aspartame 
No. Conc. Revertant colonies/plate 
(µg/plate) 
  
TA 100 TA 98 
+S9 M.I. -S9 M.I. +S9 M.I. -S9 M.I. 
          1 190 + 150 143 0.77 72 0.68 99 1.11 92 1.27 
2 380 + 300 167 0.9 86 0.81 163 1.83 105 1.45 
3 760 + 600 196 1.06 92 0.87 183 2.05 113 1.56 
4 1520 + 1200 206 1.12 124 1.18 190 2.13 129 1.79 
5 3040 + 2400 155 0.84 80 0.76 154 1.73 62 0.86 
Negative control 0 184   105   89   72   
Positive Control 5 2096 11.39 758 7.21 563 6.325 360 5 
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Table 7: Mutagentic potential of sitagliptin and acesulfame-K in combination 
 
Sitagliptin + acesulfame-K 
No. Conc. Revertant Colonies/plate 
(µg/plate) 
  
TA 100 TA 98 
+S9 M.I. -S9 M.I. +S9 M.I. -S9 M.I. 
          1 190 + 100 134 0.72 73 0.69 43 0.48 40 0.55 
2 380 + 200 189 1.02 96 0.91 52 0.58 60 0.83 
3 760 + 400 196 1.06 136 1.29 96 1.07 236 3.27 
4 1520 + 800 246 1.33 156 1.48 122 1.37 144 2 
5 3040 + 1600 163 0.88 130 1.23 96 1.07 108 1.5 
Negative 
Control 
0 184   105   89   72   
Positive 
Control  
5 2096 11.39 758 7.21 563 6.325 360 5 
 
Combined doses of sitagliptin + acesulfame-K 
(Fig 3) when investigated for genotoxicity using 
comet assay, the damage indices of 3, 7, 17, 22 
and 37 were calculated against the combined 
doses of 190+100 µg/mL, 380+200 µg/mL, 
760+400 µg/mL, 1520+800 µg/mL and 
3040+1600 µg/mL. When sitagliptin + 
acesulfame-k results compared with the 
genotoxic effect of sitagliptin alone, no significant 
difference in the result occurred. Sitagliptin + 
acesulfame-k when evaluated in combination 
(Table 7) for mutagenicity results exhibited 
mutagenic potential at the combined doses of 
760+400 µg/plate and 1520+800 µg/plate against 
TA98 without metabolic activation system. The 
results of combined doses of sitagliptin and 
acesulfame-k when compared with sitagliptin 




Sitagliptin was genotoxic at its higher 
concentrations.  DNA damage was maximum at 
the concentration of 1520 µg/mL and 3040 
µg/mL. The damage indices at these 
concentrations were 9 and 20 respectively. 
These findings were in accordance to a clinical 
review in which peripheral lymphocytes of the 
type 2 diabetic patients were used and results 
exhibited that the sitagliptin demonstrated 
genotoxic impacts [14]. 
 
The saccharin also showed genotoxic potential. 
These outcomes were in line with Ashby and 
Ishidate's review [15] who reported the 
clastogenic impacts of saccharin on the Chinese 
hamster lung (CHL) fibroblasts. They 
recommended that the genotoxic impact of the 
saccharin may be because of the salts particles. 
On the other hand the positive mutagenic results 
of saccharin might be due to the impurities of the 
saccharin which showed greater mutagenic 
effects on TA98 than TA100 strains of 
Salmonella typhimurium [16]. 
 
The comet results of Aspartame were similar to 
the positive dose dependent chromosome 
aberration test [17]. However the positive 
mutagenic results of aspartame endorse the 
statement that aspartame possesses mutagenic 
activity and is capable of causing more than one 
type of cancer [18]. Aspartame in gastrointestinal 
tract is broken into its metabolites, aspartic acid, 
methanol and phenylalanine. Methanol is further 
oxidized in to formaldehyde and formate. Formic 
acid is the reason for most of the harmful effects 
in human and animals [19]. 
 
Genotoxic and mutagenic positive results of 
acesulfame-k indicates that acesulfame-K is 
capable of interacting with the genetic material of 
the cell only at high doses [20]. 
 
When the sitagliptin and the artificial sweeteners 
were evaluated in combination the results depicts 





Sitagliptin exhibits mutagenic potential at higher 
concentrations alone and in combination with 
artificial sweeteners. It also exhibits genotoxic 
behavior in a dose-dependant manner. Although 
sitagliptin, in combination with artificial 
sweetener, did not display a higher genotoxicity 
relative to compound alone, care still need to be 
taken by diabetic patients while being treated 
with the anti-diabetic drugs and concurrently 
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